第三届国际呼吸道病毒学会抗病毒药物小组会议综述——临床管理进展
Overview of the 3rd isirv-Antiviral Group Conference--advances in clinical management.
作者信息
Hurt Aeron C, Hui David S, Hay Alan, Hayden Frederick G
机构信息
WHO Collaborating Centre for Reference and Research on Influenza, VIDRL at the Peter Doherty Institute for Infection and Immunity, Parkville, Vic., Australia; Melbourne School of Population and Global Health, University of Melbourne, Parkville, Vic., Australia.
出版信息
Influenza Other Respir Viruses. 2015 Jan;9(1):20-31. doi: 10.1111/irv.12293. Epub 2014 Nov 15.
Abstract
This review highlights the main points which emerged from the presentations and discussions at the 3rd isirv-Antiviral Group Conference - advances in clinical management. The conference covered emerging and potentially pandemic influenza viruses and discussed novel/pre-licensure therapeutics and currently approved antivirals and vaccines for the control of influenza. Current data on approved and novel treatments for non-influenza respiratory viruses such as MERS-CoV, respiratory syncytial virus (RSV) and rhinoviruses and the challenges of treating immunocompromised patients with respiratory infections was highlighted.
摘要
本综述重点介绍了第三届国际流感研究与疫苗学会抗病毒小组会议——临床管理进展中的报告和讨论所产生的要点。会议涵盖了新出现的和可能引发大流行的流感病毒，并讨论了用于控制流感的新型/预许可疗法以及目前已批准的抗病毒药物和疫苗。还重点介绍了关于中东呼吸综合征冠状病毒、呼吸道合胞病毒（RSV）和鼻病毒等非流感呼吸道病毒的已批准和新型治疗方法的当前数据，以及治疗免疫功能低下的呼吸道感染患者所面临的挑战。
相似文献
1
Overview of the 3rd isirv-Antiviral Group Conference--advances in clinical management.第三届国际呼吸道病毒学会抗病毒药物小组会议综述——临床管理进展
Influenza Other Respir Viruses. 2015 Jan;9(1):20-31. doi: 10.1111/irv.12293. Epub 2014 Nov 15.
2
Meeting report: 4th ISIRV antiviral group conference: Novel antiviral therapies for influenza and other respiratory viruses.会议报告：第四届国际流感病毒研究与疫苗协会抗病毒小组会议：流感及其他呼吸道病毒的新型抗病毒疗法
Antiviral Res. 2016 May;129:21-38. doi: 10.1016/j.antiviral.2016.01.012. Epub 2016 Feb 9.
3
18th International Conference on Antiviral Research. Respiratory viruses.第18届国际抗病毒研究会议。呼吸道病毒。
IDrugs. 2005 Jun;8(6):465-6.
4
Advances in respiratory virus therapeutics - A meeting report from the 6th isirv Antiviral Group conference.呼吸道病毒治疗学的进展——第六届国际抗病毒研究学会（isirv）抗病毒小组会议报告
Antiviral Res. 2019 Jul;167:45-67. doi: 10.1016/j.antiviral.2019.04.006. Epub 2019 Apr 8.
5
Therapeutic potential of resveratrol against emerging respiratory viral infections.白藜芦醇对抗新兴呼吸道病毒感染的治疗潜力。
Pharmacol Ther. 2020 Oct;214:107613. doi: 10.1016/j.pharmthera.2020.107613. Epub 2020 Jun 17.
6
Antiviral therapy for respiratory viral infections in immunocompromised patients.免疫功能低下患者呼吸道病毒感染的抗病毒治疗。
Expert Rev Anti Infect Ther. 2017 Apr;15(4):401-415. doi: 10.1080/14787210.2017.1279970. Epub 2017 Jan 16.
7
Prevention and treatment of respiratory viral infections: Presentations on antivirals, traditional therapies and host-directed interventions at the 5th ISIRV Antiviral Group conference.呼吸道病毒感染的预防和治疗：第五届国际抗病毒研究学会（ISIRV）抗病毒小组会议上关于抗病毒药物、传统疗法和宿主导向干预的报告。
Antiviral Res. 2018 Jan;149:118-142. doi: 10.1016/j.antiviral.2017.11.013. Epub 2017 Nov 21.
8
High prevalence of common respiratory viruses and no evidence of Middle East respiratory syndrome coronavirus in Hajj pilgrims returning to Ghana, 2013.2013年返回加纳的朝觐者中常见呼吸道病毒的高流行率以及无中东呼吸综合征冠状病毒感染证据
Trop Med Int Health. 2015 Jun;20(6):807-12. doi: 10.1111/tmi.12482. Epub 2015 Mar 3.
9
Respiratory viruses and children.呼吸道病毒与儿童。
J Infect. 2016 Jul 5;72 Suppl:S29-33. doi: 10.1016/j.jinf.2016.04.019. Epub 2016 May 10.
10
VII International Symposium on Respiratory Viral Infections.第七届国际呼吸道病毒感染研讨会
Antivir Ther. 2007;12(4 Pt B):671-93.
引用本文的文献
1
Identification of multi-targeting natural antiviral peptides to impede SARS-CoV-2 infection.鉴定多靶点天然抗病毒肽以阻止新型冠状病毒感染。
Struct Chem. 2022 Dec 17:1-16. doi: 10.1007/s11224-022-02113-9.
2
Epidemiology and outcomes of hospitalized adults with respiratory syncytial virus: A 6-year retrospective study.住院成人呼吸道合胞病毒感染的流行病学和结局：一项 6 年回顾性研究。
Influenza Other Respir Viruses. 2019 Jul;13(4):331-338. doi: 10.1111/irv.12643. Epub 2019 Apr 11.
3
Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil.描述使用内切酶抑制剂巴洛沙韦治疗诱导的流感病毒变异体。
Sci Rep. 2018 Jun 25;8(1):9633. doi: 10.1038/s41598-018-27890-4.
4
A clinical approach to the threat of emerging influenza viruses in the Asia-Pacific region.应对亚太地区新型流感病毒威胁的临床方法。
Respirology. 2017 Oct;22(7):1300-1312. doi: 10.1111/resp.13114. Epub 2017 Jul 5.
5
Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.宿主二氢叶酸还原酶（DHFR）导向的环氯胍类似物，具有抗流感病毒和呼吸道合胞病毒的活性。
Eur J Med Chem. 2017 Jul 28;135:467-478. doi: 10.1016/j.ejmech.2017.04.070. Epub 2017 Apr 27.
6
Antiviral Treatments.抗病毒治疗。
Clin Chest Med. 2017 Mar;38(1):139-153. doi: 10.1016/j.ccm.2016.11.008. Epub 2016 Dec 13.
7
Influenza antivirals currently in late-phase clinical trial.目前处于后期临床试验阶段的流感抗病毒药物。
Influenza Other Respir Viruses. 2017 May;11(3):240-246. doi: 10.1111/irv.12446. Epub 2017 Feb 28.
8
Passive immunization for influenza through antibody therapies, a review of the pipeline, challenges and potential applications.通过抗体疗法进行流感被动免疫：管线、挑战及潜在应用综述
Vaccine. 2016 Oct 26;34(45):5442-5448. doi: 10.1016/j.vaccine.2016.08.057. Epub 2016 Sep 9.
9
Inhibition of Influenza Virus Replication by DNA Aptamers Targeting a Cellular Component of Translation Initiation.靶向翻译起始细胞组分的DNA适配体对流感病毒复制的抑制作用
Mol Ther Nucleic Acids. 2016 Apr 12;5(4):e308. doi: 10.1038/mtna.2016.20.
10
Respiratory Infections in the U.S. Military: Recent Experience and Control.美国军队中的呼吸道感染：近期经验与防控
Clin Microbiol Rev. 2015 Jul;28(3):743-800. doi: 10.1128/CMR.00039-14.
本文引用的文献
1
Nitazoxanide: a first-in-class broad-spectrum antiviral agent.硝唑尼特：一种一流的广谱抗病毒药物。
Antiviral Res. 2014 Oct;110:94-103. doi: 10.1016/j.antiviral.2014.07.014. Epub 2014 Aug 7.
2
The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis.恢复期血浆和高效免疫球蛋白治疗病毒性病因严重急性呼吸道感染的有效性：系统评价与探索性Meta分析
J Infect Dis. 2015 Jan 1;211(1):80-90. doi: 10.1093/infdis/jiu396. Epub 2014 Jul 16.
3
The R292K mutation that confers resistance to neuraminidase inhibitors leads to competitive fitness loss of A/Shanghai/1/2013 (H7N9) influenza virus in ferrets.赋予对神经氨酸酶抑制剂耐药性的R292K突变导致A/上海/1/2013（H7N9）流感病毒在雪貂中的竞争适应性丧失。
J Infect Dis. 2014 Dec 15;210(12):1900-8. doi: 10.1093/infdis/jiu353. Epub 2014 Jun 20.
4
The effect of inhaled IFN-β on worsening of asthma symptoms caused by viral infections. A randomized trial.吸入式干扰素-β对病毒感染所致哮喘症状恶化的影响。一项随机试验。
Am J Respir Crit Care Med. 2014 Jul 15;190(2):145-54. doi: 10.1164/rccm.201312-2235OC.
5
Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: a double-blind, randomised, placebo-controlled, phase 2b/3 trial.硝唑尼特治疗成人和青少年急性单纯性流感的效果：一项双盲、随机、安慰剂对照、2b/3 期临床试验。
Lancet Infect Dis. 2014 Jul;14(7):609-18. doi: 10.1016/S1473-3099(14)70717-0. Epub 2014 May 19.
6
Evaluation of oseltamivir prophylaxis regimens for reducing influenza virus infection, transmission and disease severity in a ferret model of household contact.在雪貂家庭接触模型中评估奥司他韦预防方案对减少流感病毒感染、传播和疾病严重程度的作用。
J Antimicrob Chemother. 2014 Sep;69(9):2458-69. doi: 10.1093/jac/dku146. Epub 2014 May 19.
7
Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data.神经氨酸酶抑制剂在降低甲型 H1N1pdm09 流感病毒感染住院患者死亡率中的效果：一项个体参与者数据的荟萃分析。
Lancet Respir Med. 2014 May;2(5):395-404. doi: 10.1016/S2213-2600(14)70041-4. Epub 2014 Mar 19.
8
Prevention of influenza by targeting host receptors using engineered proteins.利用工程蛋白靶向宿主受体预防流感。
Proc Natl Acad Sci U S A. 2014 Apr 29;111(17):6401-6. doi: 10.1073/pnas.1404205111. Epub 2014 Apr 14.
9
Influenza symptoms and their impact on elderly adults: randomised trial of AS03-adjuvanted or non-adjuvanted inactivated trivalent seasonal influenza vaccines.流感症状及其对老年人的影响：AS03 佐剂或非佐剂三价季节性流感灭活疫苗的随机试验。
Influenza Other Respir Viruses. 2014 Jul;8(4):452-62. doi: 10.1111/irv.12245. Epub 2014 Apr 4.
10
Estimating the fitness advantage conferred by permissive neuraminidase mutations in recent oseltamivir-resistant A(H1N1)pdm09 influenza viruses.评估近期耐奥司他韦的甲型H1N1pdm09流感病毒中允许性神经氨酸酶突变所带来的适应性优势。
PLoS Pathog. 2014 Apr 3;10(4):e1004065. doi: 10.1371/journal.ppat.1004065. eCollection 2014 Apr.
Zotero 插件